Under the agreement, all researchers at the NCI will have access to Ingenuity's Pathway Analysis software, which includes a curated database of protein, gene, cell, tissue, drug, and disease networks.
Ingenuity aims to gain a stronger foothold in the academic and government research world this year, CEO Jake Leschly said in a company statement.